bristol myers squibb co alliance with isis to focus on gene tied to cholesterol bristol myers squibb co and isis pharmaceuticals inc agreed to collaborate on drugs focusing on a gene thought to boost bad cholesterol the agreement involves the development and commercialization of treatments targeting the gene pcsk which is thought to help degrade low density lipoprotein receptors lower amounts of those receptors help cause higher amounts of ldl cholesterol or bad cholesterol isis a carlsbad calif biotechnology company is licensing to bristol exclusive access to its pcsk research program which recently shed light on how the gene contributes to higher levels of ldl cholesterol bristol a new york drug maker will fund all activities under the collaboration it will pay isis &# million upfront as a licensing fee at least &# million over three years for research funding and as much as &# million based on milestones for drugs that come out of the deal 
